ProfileGDS5678 / 1444727_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 53% 54% 54% 52% 54% 58% 59% 54% 54% 54% 54% 54% 54% 55% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 13.3593453
GSM967853U87-EV human glioblastoma xenograft - Control 23.3389254
GSM967854U87-EV human glioblastoma xenograft - Control 33.3472254
GSM967855U87-EV human glioblastoma xenograft - Control 43.1931752
GSM967856U87-EV human glioblastoma xenograft - Control 53.285354
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 13.5871758
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 23.6115459
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 33.3185254
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 43.3024254
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 13.3283854
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 23.326454
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 33.3111954
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 43.3546754
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 53.3657155